The Potential Role of Aripiprazole Augmentation for Major Depressive Disorder with Anxious Distress in Naturalistic Treatment Setting
Seung-Hoon Lee1,*, Kyung Ho Lee2,3,*, Tae Sun Han4, Changsu Han1, Won-Myong Bahk5, Soo-Jung Lee5, Ashwin A. Patkar6, Prakash S. Masand7, Chi-Un Pae3,5
1Department of Psychiatry, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea
2Department of Dermatology, Bucheon St. Mary’s Hospital, The Catholic University of Korea College of Medicine, Bucheon, Korea
3Cell Death Disease Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea
4Yonsei St. Mary’s Mental Clinic, Bucheon, Korea
5Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Korea
6Avance Psychiatry at Centers of Excellence, Raleigh, NC, USA
7Duke-NUS Medical School, Singapore
Correspondence to: Chi-Un Pae
Department of Psychiatry, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 327 Sosa-ro, Wonmi-gu, Bucheon 14647, Korea

*These authors contributed equally to this work.
Received: June 15, 2023; Revised: August 8, 2023; Accepted: August 13, 2023; Published online: February 4, 2024.
© The Korean College of Neuropsychopharmacology. All rights reserved.

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective: This study tried to observe clinical benefit of aripiprazole augmentation (ARPA) treatment for major depressive disorder with anxious distress (MDDA) in routine practice.
Methods: Retrospective chart review (n = 41) was conducted for clinical benefit of ARPA in patients with MDDA in routine practice. The primary endpoint was the mean change of Hamilton Anxiety Rating scale (HAMA) total scores from baseline to the endpoint. Additional secondary endpoints were also retrieved.
Results: The changes of primary endpoint HAMA (t = 5.731, −4.6, p = 0.001), and secondary endpoints including Hamilton Depression Rating scale (HAMD, t = 4.284, −3.4, p < 0.001), Clinical Global Impression-Clinical Benefit (CGI-CB, −0.9, t = 1.821, p = 0.026), and Clinical Global Impression Score-Severity (CGI-S, t = 3.556, −0.4, p < 0.001) scores were also significantly improved during the study. No significant adverse events were observed.
Conclusion: This study has shown additional benefit of ARPA treatment for MDDA patients in routine practice. However, adequately-powered and well-controlled studies are necessary for generalization of the present findings.
Keywords: Aripiprazole; Depressive disorder; Anxious distress; Additional benefit; Adverse event; Chart review

This Article